MTOR and breast carcinoma: In conclusion, we have recently seen significant improvements in PFS in selected breast cancer patients based on novel drug combinations involving AIs, mTOR inhibitors, HER2 directed therapies, PI3K inhibitors and CDK4/6 inhibitors.